Schreiner MediPharm is a founding member of the “Alliance to Zero”
Enhancing sustainability along the pharmaceutical supply chain: As founders of the “Alliance to Zero,” eight renowned players have been jointly pursuing this aim since June 2021. The purpose of the non-profit partnership is to support pharmaceutical and biotech companies in their transition to net-zero emissions in line with the Paris Climate Agreement. Schreiner MediPharm, as an expert in pharmaceutical specialty labels, is one of the founding members.
The Alliance to Zero pursues the goal of launching net-zero pharmaceutical products in regulated markets by 2030 at the latest. To achieve this, the founding members have committed to developing a joint net-zero offering by 2026 to provide pharmaceutical companies with enough time to finish their total product on this basis.
The Alliance has developed a roadmap for a net-zero emissions concept for pharmaceutical production and the supply chain. Currently necessary steps are being developed and a harmonised language as well as principles for evaluating and monitoring the entire emissions footprint of the pharmaceutical end products are being defined. In addition, the Alliance is planning to collaborate with academic and non-profit organisations pursuing similar goals.
Dr Thomas Schweizer, president of Schreiner MediPharm emphasises the importance of the company’s membership in the Alliance: “For Schreiner MediPharm, as a pioneer in the production of innovative functional labels, sustainability starts as early as in product development that considers all lifecycles in order to achieve a reduced environmental footprint. For us, co-founding the Alliance to Zero means another important step toward holistic sustainability. We are convinced that, together with the other alliance partners, we will be able to drive the development of net-zero pharmaceutical products.”
In addition to Schreiner MediPharm, the founding members of the Alliance represent other renowned companies of the pharmaceutical and biotech value chain: Dätwyler, Harro Höfliger, HealthBeacon, Körber Pharma, SCHOTT, Sharp, and Ypsomed. Thus, the Alliance encompasses component suppliers, machine manufacturers and assembly/manufacturing service providers, manufacturers of primary and secondary packaging, and companies that are responsible for the final assembly of the products, or that handle products that have been returned after use.
The founding members of the Alliance to Zero regard their collaboration along the pharmaceutical supply chain as an important step in driving fundamental change to improve the climate footprint. The close collaboration across traditional company boundaries as well as the specialised expertise and individual know-how of each cooperation partner results in the development of holistic solutions that will have a positive impact on the pharmaceutical industry.
Caption: The Alliance to Zero is an important step on the road to net-zero emissions in the pharmaceutical supply chain (photo: Schreiner Group)